Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02576717 · ClinicalTrials.gov registry record · Phase 3
A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis
A Phase 3 study, sponsored by Celgene.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,494
- Enrollment target
NCT02576717: Completed Phase 3 study, sponsored by Celgene.
NCT02576717 is a Phase 3 study that has completed, run by Celgene. The registered enrollment target is 2,494 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (223% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02576717, a Phase 3 study, has completed, sponsored by Celgene.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,494 participants
- Enrollment target
Study Summary
The purpose of the trial is to determine the safety and efficacy of RPC1063 in patients with relapsing multiple sclerosis.
Primary Outcome
An AE is any untoward medical occurrence in a patient or clinical investigation patient administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease temporarily associated with the use of medicinal product, whether or not considered related to the investigational medicinal product.
Interventions
- DRUG RPC1063
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,494 participants |
| Start Date | 2015-10-16 |
| Est. Completion | 2023-01-05 |
| Phase | Phase 3 |
What the finished NCT02576717 record still lists
NCT02576717 is an interventional study that assigns participants to a tested intervention. Its 2,494 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (223% higher).
The record links to 0 conditions, and to 1 intervention - of which RPC1063 is the first listed.
NCT02576717 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02576717 about?
NCT02576717 is a clinical study titled "A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis". The purpose of the trial is to determine the safety and efficacy of RPC1063 in patients with relapsing multiple sclerosis.
What is the current status of trial NCT02576717?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,494 participants. The study started on 2015-10-16. Estimated completion is 2023-01-05.
What interventions are being tested in trial NCT02576717?
The interventions under investigation include: RPC1063 (DRUG).
Who is sponsoring clinical trial NCT02576717?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02576717's enrollment target sits among peer trials
2,494 88th of 2000 higher than 1,913 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001160 · 2,500 participants
Studies on Tumors of the Thyroid
- NCT01904188 · 2,500 participants
Clinical Microbial Species & Antibiotic Resistance ID in ED Patients Presenting With Infection - is Rapid ID Possible & Accurate?
- NCT02257229 · 2,500 participants
Prospective Evaluation of Treatment for Clubfoot
- NCT02530658 · 2,500 participants
Next Generation Sequencing of Normal Tissues Prospectively in Pediatric Oncology Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI